Gapping down
In reaction to earnings/guidance:
- CHGG -31.4%, SMLR -24.5%, ESPR -7.8%, NBIX -7.7%, EVER -7.6%, GNRC -6.5%, BWXT -5%, PNTG -5%, LCII -5%, ADTN -4.8%, RIG -4.5%, SRCL -4.2%, VRNS -4.1%, WAT -4%, LEG -3.5%, MOS -3.5%, RMBS -3.4%, GPN -3.4%, BP -2.7%, BLMN -2.6%, PLOW -2.3%, TWNK -2.2%, SAGE -2.1%, CRSR -2.1%, EL -1.9%, USAC -1.7%, BCC -1.6%, NXPI -1.6%, HSC -1.5%, CMI -1.4%, APO -1.1%, CACC -1%
Other news:
- CLNN -27.3% (announces top-line results from Phase 2 RESCUE-ALS clinical trial)
- LEGN -9.8% (FDA extends PDUFA target date for ciltacabtagene autoleucel to Feb 28, 2022)
- IVC -7.9% (to be removed from S&P SmallCap 600)
- VRT -5.1% (stock offering)
- ABR -4.1% (prices offering of 7.5 mln shares of common stock for gross proceeds of $147.8 mln)
- TSLA -3.8% (to recall 11,700 vehicles over communication problem - CNBC; Elon Musk responds to tweet about TSLA's stock price)
- ACAD -2.2% (names new COO)
- SHLX -1.3% (common unit offering)
- NEP -1.2% (stock offering)
- IGT -1.2% (signs licensing deal with Authentic Brands, owner of Marilyn Monroe Estate)
- DD -1.2% (acquired ROG for $277 per share; also reported earnings)
- ABG -1.1% (stock offering)
- PI -1% (convertible notes offering)
Analyst comments:
- IQ -4.4% (downgraded to Neutral from Buy at UBS)
- YY -4.3% (downgraded to Sell from Neutral at Goldman)
- EXPE -1.3% (downgraded to Neutral from Overweight at Atlantic Equities )
- XOM -0.9% (downgraded to Sell from Hold at Truist)
